Trial of VELCADE in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study seeks to test the Efficacy in terms of rates of disease response in metastatic
nasopharyngeal carcinoma of the standard dose of velcade 1.3 mg/m2 given at the day 1,4,8,and
11 every 21 days schedule. The study uses a Simons 2 stage design and will enroll between
15-25 patients. Secondary endpoints studied include Pharmacokinetics, toxicities, EBV viral
load and molecular characterization of EBV in plasma.